Efficacy and safety of niraparib combined with anlotinib maintenance retreatment in platinum-sensitive recurrent ovarian cancer patients who previously received PARP inhibitor: An open-label, single-arm, prospective, exploratory phase II study (1265)

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2023-09, Vol.176, p.S168-S168
Main Authors: Jin, Ying, Pan, Lingya, Shan, Ying, Li, Yan, Gu, Yu, Wang, Wei
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2023.06.174